Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Opioids composition for treating withdrawal symptoms of morphine addiction

A technology for opioids and withdrawal symptoms, which is applied in the field of opioids and clinical detoxification substitution therapy, can solve problems such as aggravation, obvious withdrawal reaction, secondary addiction, etc., so as to improve the quality of life and avoid secondary addiction. , the effect of reducing withdrawal symptoms

Inactive Publication Date: 2018-02-02
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although weak opioids can control withdrawal symptoms, they can easily cause secondary addiction and have a central inhibitory effect
Non-opioid drugs are not addictive, but the withdrawal reaction is obvious or even worse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Opioids composition for treating withdrawal symptoms of morphine addiction
  • Opioids composition for treating withdrawal symptoms of morphine addiction
  • Opioids composition for treating withdrawal symptoms of morphine addiction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Morphine: 10-100mg / kg

[0022] Buprenorphine: 0.4mg / kg

[0023] Dezocine: 0.4mg / kg

[0024] Mixed solution A: buprenorphine: pentazocine = 1:1, that is, buprenorphine and pentazocine are 0.2mg / kg and 0.2mg / kg respectively, dissolved in DMSO and diluted to 1ml, passed through the aperture After filtering with 0.22μM filter paper, subpackage, seal, sterilize and store at 4°C, and freezing is strictly prohibited.

[0025] Mixed solution B: buprenorphine: tramadol = 1:1, that is, buprenorphine and tramadol are 0.2mg / kg and 0.2mg / kg respectively, dissolved in DMSO and diluted to 1ml, passed through a pore size of 0.22μM After filtering with filter paper, subpackage, seal, sterilize and store at 4°C. Freezing is strictly prohibited.

[0026] Mixed solution C: buprenorphine: dezocine = 1:1, that is, buprenorphine and dezocine are 0.2mg / kg and 0.2mg / kg respectively, dissolved in DMSO and diluted to 1ml, passed through a pore size of 0.22μM After filtering with filter paper,...

Embodiment 2

[0035] After the successful establishment of the morphine addiction model, the addicted rats were randomly divided into 11 groups, 20 in each group. The blank control group was given the same dose of normal saline or natural withdrawal, and the other groups were given buprenorphine and dezocine respectively. , mixed solution A, mixed solution B, mixed solution C, mixed solution D, mixed solution E, mixed solution F, CPP was measured after six consecutive days of replacement therapy. The results are shown in Table 2. The white box residence time of rats after addiction was significantly higher than that before addiction, indicating that the morphine addiction model was successful. The replacement therapy in the experimental group can significantly reduce the CPP value of morphine-addicted rats (P<0.05), but the improvement effect of mixture A and mixture B on CPP is not as good as that of buprenorphine alone, and the therapeutic effect of mixture E is obvious It is worse than ot...

Embodiment 3

[0040] After the successful establishment of the morphine addiction model, the addicted rats were randomly divided into 11 groups, 20 in each group. The blank control group was given the same dose of normal saline or natural withdrawal, and the other groups were given buprenorphine and dezocine respectively. , Mixed Solution A, Mixed Solution B, Mixed Solution C, Mixed Solution D, Mixed Solution E, Mixed Solution F, the withdrawal score was performed after six consecutive days of substitution therapy. The result is as figure 2 As shown, after the replacement treatment of the experimental group, the effect of mixed solution A and mixed solution B on improving withdrawal symptoms was not as good as that of buprenorphine alone, and the withdrawal symptoms of rats in the combined use of buprenorphine and dezocine group were significantly reduced ( P<0.05), and the withdrawal symptoms of the mixture E are the most significant, indicating that the combined use of buprenorphine, pen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of pharmaceutical technologies, in particular to an opioids composition for treating withdrawal symptoms of morphine addiction. The opioids composition comprises buprenorphine and dezocine. A weight ratio of the buprenorphine to the dezocine is 1:6-1:1. The opioids composition has the advantages that obvious effects of treating the morphine addiction can be realized by the opioids composition; the withdrawal symptoms can be obviously relieved, the opioids composition is little in side effect, secondary addiction can be prevented, and the quality of life can be effectively improved.

Description

technical field [0001] The invention relates to the field of pharmaceutical compositions, in particular, it is an opioid drug used for treating morphine addiction and preventing related withdrawal symptoms with less side effects, and is applied to clinical detoxification and substitution therapy. Background technique [0002] Opioid addiction is extremely harmful to patients and society, and the current method of treating morphine addiction is mainly to use weak opioids for progressive substitution therapy, but the side effects are obvious. Withdrawal symptoms after morphine addiction are obvious, mainly manifested as autonomic hyperfunction, the body is in a state of strong excitement, manifested as symptoms such as irritability, hyperactivity, diarrhea, and tearing. The drugs commonly used to replace morphine addiction at this stage are mainly weak opioid drugs such as methadone and buprenorphine, and non-opioid drugs such as naloxone. Although weak opioids can control wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/485A61K31/135A61P25/36
Inventor 孔二亮吴飞翔何焱张金旻王洪乾俞卫锋
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com